https://doi.org/10.4081/jbr.2019.7742
Expression of p53 and p21 in bladder carcinoma of Iraqi patients
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 24 June 2019
Bladder cancer is an abnormal cellular multiplication without control arising from the urinary bladder urothelium. Cells cycle is a strictly controlled process regulated by protein complexes composed of cyclins and cyclin-dependent kinases and also by several tumor suppressor gene protein products acting at the Go/G1 checkpoint of the cell-cycle. This study was designed to evaluate the frequency of p53 and p21 expression as biomarkers to monitor the disease and compare the results with those of others. Seventy-three tumors with different stages and grades were collected from patients with bladder carcinoma and ten normal bladder biopsies from forensic autopsy. Sections were immunohistochemically stained for p53 and p21. Results revealed that p53 positive immune reactivity was observed in (57.5%) which were exclusively nuclear and no immune reactivity detectable in (42.5%) of tumors, while all normal tissues expressed negative patterns. Positive immune staining of p21 was recorded in (69.5%) and negative p21 immune staining was recorded in 22 (31.1%), as well as ten normal urothelium. Statistically p53 and p21 over-expression was significantly related to stage and grade of tumors (P<0.05).
Downloads
• Al-Biaty,H(2015). Study of Toll Like Receptors (TLR-2 and 4) and Selected Biomarkers in Bladder Cancer Patients. Ph.D thesis , College of Medicine . The University of Al-Mustansiriya.
• Choi, J.; Kim,Y.; Lee , J. and Y.,Kim (2013). CD74 Expression is Increased in High-Grade, Invasive Urothelial Carcinoma of the Bladder. International Journal of Urology., 20: 251–255.
• Duggana, B. and K., Williamson (2004). Molecular Markers for predicting Recurrence, progression and outcomes of Bladder Cancer (do the poster boys need new posters?). Curr Opin Urol., 14:277–286.
• Girardini, J.;Walerych, D. and D., Sal (2014).Cooperation of p53 Mutations with other Oncogenic Alterations in Cancer. Subcell Biochem. ;85:41-70.
• Green, D. and G.,Kroemer (2009). Cytoplasmic Functions of the Tumor Suppressor p53. Nature ., 458:1127–1130.
• Grivennikov, S.; Florian, R.; Greten, Y. and M., Karin(2010).
Immunity, Inflammation, and Cancer. Cell 140: 883–899..,.
• Hai-Bin, Z.; Yang, K.; Xie, Y.;Lin, Y.; Mao,Q. and L., Xie((2013). Silencing of Mutant p53 by siRNA induces Cell Cycle Arrest and Apoptosis in Human Bladder Cancer Cells. World Journal of Surgical Oncology.,11(22):11-29.
• Harper ,J.; Adami ,G.; Wei, N.; Keyomarsi, K. and S., Elledge (2010). "The p21 Cdk-Interacting protein Cip1 is a potent Inhibitor of G1 cyclin-dependent kinases". Cell 75(4): 805–16.
• Kausch,A. (2002) Molecular Aspects of Bladder Cancer .Europan Urology.,41:15-29.
• Keymoosi, H.; Gheytanchi, E.; Asgari, M.; Shariftabrizi, A. and Z., Madjd(2014). ALDH1 in Combination with CD44 as Putative Cancer Stem Cell Markers are Correlated with Poor Prognosis in Urothelial Carcinoma of the Urinary Bladder. Asian Pacific Journal of Cancer Prevention, 15(5):2013-2020.
• Madka, V.; Yuting ,Z.; Li, Q.; Altaf, M.; Sindhwani, P.; Lightfoot, S.; Wu, X.; Kopelovich, L. and R. Chinthalapally (2013).p53 Stabilizing Agent prevent Growth and Invasion of Urothelial Cancer. Neoplasia ., 15( 8):966-974.
• McKenzie, P.; Danks, M.; Kriwacki, R. and L., Harris (2003). "P21Waf1/Cip1 Dysfunction in Neuroblastoma: a Novel Mechanism of Attenuating G0-G1 Cell Cycle Arrest". Cancer Res. ,63 (13): 3840–3844.
• Noroozinia, F.; Fahmideh, A.; Yekta, Z.; Rouhrazi, H. and Y., Rasmi(2015). Expression of CD44 and P53 in Renal Cell Carcinoma: Association with Tumor Subtypes. Saudi J Kidney Dis Transpl .,25(1):79-84.
• Olsson, H.; Hultman, P.; Monsef, N.; Rosell, J. and S., Jahn¬son (2012). Immunohistochemical Evaluation of Cell Cycle Regulators: Impact on predicting progno¬sis in stage T1 Urinary Bladder Cancer. ISRN Urol 12;: 9081-9089.
• Puzio-Kuter, A.; Castillo-Martin,M.; Kinkade, C.; Wang, X.; Shen, T.; Matos, T.; Shen, M.; Cordon-Cardo, C. and C., Abate-Shen (2015). Inactivation of p53 and Pten promotes Invasive Bladder Cancer. GENES & DEVELOPMENT, 23:675–680
• Resnick ,M.; Bassett, J. and P., Clark (2013). Manage¬ment of Superficial and Muscle-Invasive Uro-thelial Cancers of the Bladder. Curr Opin Oncol ., 25: 281-288.
• Shahrokh, F.; Shariat, H.;Zhou, J.; Kim, J.; Gustavo, E.; Benedict, F. and S., Lerner (2004). p53, p21, pRB, and p16 Expression Predict Clinical Outcome in Cystectomy With Bladder Cancer. J Clin Oncol., 22:1014-1024.
• Siegel, R.; Naishadham, D . and A., Jemal (2012). Cancer statistics. CA Cancer J Clin.;62(1):10-29.
• Takimoto, R.; Wang, W.; Dicker, T.; Rastinejad, F.; Lyssikatos, J. and w.,Deiry (2002). The Mutant p53-Conformation Modifying Drug, CP-31398, can induce Apoptosis of Human Cancer Cells and can Stabilize Wild-type p53 protein. Cancer Biol Ther .,1(1):47–55.
• Tang, K.; Wang, C.; , Chen,Z.; Xu,H. and Y. , Zhangqun (2015). Clinicopathologic and prognostic significance of p21 (Cip1/Waf1) Expression in Bladder Cancer. Int J Clin Exp Pathol .,8(5):4999-5007.
• Tawfeeq, K. and S. Al-Talib (2012). P53 Over-Expression in Urothelial Carcinoma of the Bladder: An Immunohistochemical Study. Tikrit Medical Journal 18(2):198-211.
• Wiman, K. (2007). Restoration of wild-type p53 Function in Human Tumors: Strategies for Efficient Cancer Therapy. Adv Cancer Res., 97:321–338.
How to Cite
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.